We spoke with Teresa Quattrin (University at Buffalo, Oishei Children’s Hospital) following her presentation of the T1GER study, which investigated the effect of treatment with golimumab in children, adolescents, and young adults with newly diagnosed type 1 diabetes.
Disclosures: Tersea Quattrin discloses the following: Consultant to Janssen Research & Development
Clinical Trial, Principal Investigator at the Buffalo site: Janssen, Provention Bio, Inc., OPKO Biologics Ltd., and Ascendis.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
